CAAR T-Cell Targeting for Autoantibody B-Cell Depletion in CNS Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic approaches for neurological autoimmune diseases, particularly those targeting the central nervous system, suffer from broad and unspecific immunosuppression, failing to effectively remove autoantibody-producing B cells and leading to significant side effects.

Innovation Solution

A chimeric autoantibody receptor (CAAR) is engineered to target autoantigens bound by autoantibodies in neurological autoimmune diseases, specifically those affecting the central nervous system, allowing for selective depletion of disease-causing B cells while sparing beneficial antibody-producing cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If unspecific immunosuppression methods (steroid treatment, plasmapheresis, cyclophosphamide, rituximab) are used to remove autoantibodies, then the patient's condition improves, but significant side effects occur including infections, circulatory disorders, and depletion of beneficial antibodies

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the immune system response by creating a chimeric autoantibody receptor that specifically targets only autoantibody-producing B cells while leaving other immune cells and beneficial antibodies intact. This is achieved by designing the CAR with an autoantigen-binding domain that recognizes disease-specific autoantibodies, enabling selective depletion of pathogenic cells without broad immunosuppression

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The chimeric autoantibody receptor introduces local quality by endowing specific T cells with the ability to recognize and target only autoantibody-producing B cells through the autoantigen-binding domain. This localized targeting capability allows the therapy to act precisely on the source of autoantibodies while preserving the rest of the immune system's functionality

Inventive Principle:

Principle #3Local quality

2Quantity of substance

If plasmapheresis is used to remove autoantibodies from blood and cerebrospinal fluid, then autoantibody levels decrease, but injuries from central venous catheter and circulatory disorders occur

Engineering Contradiction:

Improveautoantibody levelsVSAvoidphysical injuries and circulatory disorders

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The invention employs the patient's own immune system to eliminate autoantibodies by engineering T cells with chimeric autoantibody receptors that specifically recognize and kill autoantibody-producing B cells. This self-service approach eliminates the need for external mechanical removal methods like plasmapheresis, avoiding associated physical injuries and circulatory complications

Inventive Principle:

Principle #25Self-service

3Reliability

If repeated autoantibody-removal procedures are performed to maintain patient improvement, then disease symptoms are controlled, but treatment complexity and patient burden increase

Engineering Contradiction:

Improvedisease controlVSAvoidtreatment procedure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The chimeric autoantibody receptor approach performs preliminary action by permanently eliminating the source of autoantibodies (autoantibody-producing B cells) rather than merely removing the autoantibodies themselves. This upstream intervention prevents continuous production of pathogenic antibodies, potentially achieving long-term remission and reducing the need for repeated treatments

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention discards the harmful autoantibody-producing B cells through selective depletion while recovering and preserving the rest of the immune system. By targeting only the pathogenic cells that produce disease-specific autoantibodies, the therapy eliminates the need for repeated broad immunosuppression or antibody removal procedures

Inventive Principle:

Principle #34Discarding and recovering

Data Source

PatentUS12617835B2Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

Publication Date: 2026.05.05 DEUT ZENT FUER NEURODEGENERATIVE ERKRANKUNGEN EV

AI summary

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.